92PVall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)
Hierro, C, Matos, I, Martin-Liberal, J, Ochoa De Olza Amat, M, Felip, E, Costa Rivas, M, Vieito Villar, M, Brana, I, Azaro, A, Perez-Gago, M C, Gros, A, Carles, J, Oaknin, A, Macarulla, T, Saura, C, pVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy269.090
Date:
October, 2018
File:
PDF, 77 KB
2018
File converter
More search results
More benefits 
